196 related articles for article (PubMed ID: 28536844)
1. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
2. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Deng H; Wang H; Wang M; Li Z; Wu Z
Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
[TBL] [Abstract][Full Text] [Related]
4.
Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1.
Wang JG; Li NN; Li HN; Cui L; Wang P
Neuropeptides; 2011 Apr; 45(2):151-6. PubMed ID: 21272935
[TBL] [Abstract][Full Text] [Related]
6. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of
Prignon A; Provost C; Alshoukr F; Wendum D; Couvelard A; Barbet J; Forgez P; Talbot JN; Gruaz-Guyon A
Mol Pharm; 2019 Jun; 16(6):2776-2784. PubMed ID: 31013092
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.
Buchegger F; Bonvin F; Kosinski M; Schaffland AO; Prior J; Reubi JC; Bläuenstein P; Tourwé D; García Garayoa E; Bischof Delaloye A
J Nucl Med; 2003 Oct; 44(10):1649-54. PubMed ID: 14530481
[TBL] [Abstract][Full Text] [Related]
10. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
Wu Z; Li L; Liu S; Yakushijin F; Yakushijin K; Horne D; Conti PS; Li Z; Kandeel F; Shively JE
J Nucl Med; 2014 Jul; 55(7):1178-84. PubMed ID: 24854793
[TBL] [Abstract][Full Text] [Related]
11. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
12.
Baum RP; Singh A; Schuchardt C; Kulkarni HR; Klette I; Wiessalla S; Osterkamp F; Reineke U; Smerling C
J Nucl Med; 2018 May; 59(5):809-814. PubMed ID: 29025990
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the Profile of [
Kanellopoulos P; Nock BA; Krenning EP; Maina T
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114537
[TBL] [Abstract][Full Text] [Related]
14. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
15. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.
García-Garayoa E; Bläuenstein P; Blanc A; Maes V; Tourwé D; Schubiger PA
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):37-47. PubMed ID: 18690434
[TBL] [Abstract][Full Text] [Related]
16. Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer.
Hodolic M; Ambrosini V; Fanti S
Nucl Med Commun; 2020 May; 41(5):411-415. PubMed ID: 32168264
[TBL] [Abstract][Full Text] [Related]
17. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
18. Imaging Neurotensin Receptor in Prostate Cancer With
Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z
Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698
[TBL] [Abstract][Full Text] [Related]
19. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors.
Bakirtzi K; Hatziapostolou M; Karagiannides I; Polytarchou C; Jaeger S; Iliopoulos D; Pothoulakis C
Gastroenterology; 2011 Nov; 141(5):1749-61.e1. PubMed ID: 21806946
[TBL] [Abstract][Full Text] [Related]
20. Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.
Torres JB; Knight JC; Mosley MJ; Kersemans V; Koustoulidou S; Allen D; Kinchesh P; Smart S; Cornelissen B
Mol Imaging Biol; 2018 Apr; 20(2):292-299. PubMed ID: 28842811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]